Phase III trial comparing 3 to 6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial

TOSCA trial investigates if 3 months of adjuvant FOLFOX4/XELOX is equally efficacious to 6 months in colon cancer. Adherence to planned program was good in both arms, with more than 5 months of therapy on average in arm 6m. Grade 3+ toxicities were higher in arm 6m, especially neuropathy. High compliance to therapy will allow correct assessment of differences between the two treatment durations.

from Cancer via ola Kala on Inoreader http://ift.tt/2c4gxPa
via IFTTT